Cabaletta Bio, Inc. CABA

Rank #1799 · Nasdaq · $0.2B market cap

⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

41.9

P/E

-2.1

P/B

1.04

ROE

-49.1%

Op. Margin

–%

Debt Ratio

14%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -2.1x, P/B 1.04x. Ranks in the top 55% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -49.1%. Ranks in the top 88% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 14%. Ranks in the top 11% of the universe. Under 100% is generally considered a safe level.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2019	–	$-0.0B	$-0.0B	$-0.0B	–	-13824
2020	–	$-0.0B	$-0.0B	$-0.0B	–	-1423
2021	–	$-0.0B	$-0.0B	$0.1B	–	-17
2022	–	$-0.0B	$-0.0B	$0.1B	–	8
2023	–	$-0.1B	$-0.1B	$0.1B	–	11
2024	–	$-0.1B	$-0.1B	$0.1B	–	17
2025	–	$-0.1B	$-0.1B	$0.2B	–	14

← See the full screener